APOL1 Genotype

If you have recent African ancestry, two specific changes in a single gene can quietly raise your risk of kidney failure decades before your routine labs show any sign of trouble. This test reads those changes directly from your DNA and tells you whether you are carrying the high-risk pattern that drives a disproportionate share of kidney disease in Black adults.

A normal creatinine, a normal eGFR, and a clean urine dipstick cannot rule this out. The risk is written into your genes from birth, and standard kidney panels measure damage that has already happened. Knowing your APOL1 (apolipoprotein L1) status lets you front-run that damage by monitoring earlier, more often, and more aggressively if your result is high-risk. There are not yet any APOL1-targeted treatments in routine clinical use, though drugs like inaxaplin are in active trials.

What the Test Actually Reads

The APOL1 gene makes a protein that circulates with your HDL particles and helps your immune system kill the parasites that cause African sleeping sickness. Two versions of this gene, called G1 and G2, became common in people with West and Central African ancestry because they protected against that infection. The same versions that protect against trypanosomes also injure the kidney's filtering cells over time.

Your APOL1 result reports which versions you carry on each of your two copies of the gene. A high-risk genotype means you carry two risk versions: G1/G1, G2/G2, or G1/G2. A low-risk genotype means you carry zero or one risk versions. The risk pattern is largely recessive, meaning two copies drives the steep increases in risk. Whether one copy alone meaningfully raises risk is still debated: a 2024 West African study found 18% higher odds of chronic kidney disease with a single risk version, while a 2024 review concluded that mild risk from one allele has not been firmly established.

A separate variant in the same gene, called N264K, can blunt the harmful effect of a G2 risk version in some carriers. Current expert guidance is that clinical APOL1 testing should report N264K status alongside the G1 and G2 calls, because it changes how the result should be acted on.

Kidney Disease Risk

Two APOL1 risk versions raise the odds of several specific kidney conditions, and the size of that risk depends on what else is happening in your body. In West Africans, carrying two risk versions was linked to roughly 25% higher odds of chronic kidney disease and 84% higher odds of focal segmental glomerulosclerosis, a scarring disease of the kidney's filters, compared with carrying none. Even one risk version raised the odds modestly, with about 18% higher odds of chronic kidney disease.

The same FSGS risk has been measured at 10- to 17-fold higher in African American cohorts in the United States, much larger than the West African figure. The reasons for the gap are unsettled and may include survival bias, differences in environmental triggers, or differences in study populations. Either way, the U.S. estimates are the more relevant numbers for African American readers.

In people living with HIV, the risk is dramatically larger. Black South Africans with two risk versions had about 89 times higher odds of HIV-associated nephropathy compared with HIV-positive people without the risk pattern. In HIV-infected children, the high-risk genotype carried almost 22 times higher odds of albuminuria, which is one of the earliest signs of kidney damage.

Once kidney disease is already present, the high-risk pattern speeds it up. In people with focal segmental glomerulosclerosis, those with the high-risk genotype were about 2.75 times more likely to lose kidney function rapidly. Among Black adults with kidney disease attributed to high blood pressure, two risk versions raised the odds of disease about 2.6-fold and were tied to higher chances of progressing to dialysis or transplant. In Ghanaian patients with lupus, the high-risk genotype was associated with a 14-fold higher risk of end-stage kidney failure and 13 times higher one-year mortality.

Heart Disease and Blood Pressure

There may also be a signal outside the kidney, though the cardiovascular evidence is mixed. In a large cohort of older African Americans, those with two risk versions had about twice the level of albuminuria, lower ankle blood flow, about 80% higher risk of a future heart attack, and shorter survival than those without two risk versions. Two separate cohorts (JHS and WHI) found that carrying two risk versions roughly doubled the odds of atherosclerotic cardiovascular disease, with odds ratios of 2.17 and 1.98.

However, larger and more recent studies have not consistently reproduced an independent cardiovascular effect. The Million Veteran Program (about 30,000 Black participants) found only a small association with coronary disease that appeared to be driven through kidney disease rather than independent of it, and the MESA study found no significant tie to atherosclerotic cardiovascular disease. A current review describes the APOL1-cardiovascular link as controversial. The honest read is that the cardiovascular story is unsettled, and most of the actionable risk currently rests on the kidney findings.

In young African Americans, each additional risk version was tied to higher systolic and diastolic blood pressure, and people with the high-risk pattern were diagnosed with hypertension two to five years earlier than peers without it.

Why Risk Varies So Much

Carrying two risk versions does not guarantee kidney disease. The lifetime risk of focal segmental glomerulosclerosis in people with the high-risk genotype is estimated at around 4%. Among people who already have chronic kidney disease, the high-risk genotype has been tied to a lifetime kidney failure risk near 15%, but that figure comes from a CKD cohort and should not be read as the lifetime risk for an otherwise healthy carrier. Most people with the high-risk pattern never develop kidney failure at all. Genome-wide studies have not found a single second gene that explains who gets sick and who does not.

Instead, the trigger appears to be environmental. Active viral infections like HIV and COVID-19, treatment with interferon, and other inflammatory conditions sharply raise the chance that the high-risk pattern actually causes disease. This is why your APOL1 result is best read together with your infection history, autoimmune status, and overall inflammatory burden. The gene loads the gun. Something else usually has to pull the trigger.

Resolving a Common Confusion

You may read that blood levels of the APOL1 protein were not linked to microalbuminuria or kidney filtration rate in a large population study. That sounds like a contradiction, but it is not. Risk here is mostly driven by the shape of the protein your genes produce, not by how much of it is circulating. This is a genotype test, not a protein level test. Higher or lower APOL1 in your blood is not the main signal. Whether your two copies of the gene carry G1 or G2 changes is. Some newer work suggests circulating variant protein may still play a contributing role in certain settings, but the genotype is what drives the clinical decisions today.

What an Out-of-Pattern Result Should Make You Do

A high-risk genotype is not a diagnosis and should not be treated as one. It is a flag that tells you and your clinician to watch your kidneys more carefully than a standard schedule would call for. If your result comes back high-risk, the most useful next steps are to confirm the variant call if your assay is a screening method like a SNP chip, to check kidney filtration and urine albumin on a regular cadence, and to evaluate any history of HIV, lupus, or interferon-based treatment that could accelerate kidney injury.

It is also worth knowing what current guidelines say. A 2024 KDIGO Controversies Conference concluded that the evidence is not yet sufficient to recommend routine APOL1 population screening, and that an APOL1 result on its own is not directly actionable in the way an LDL-C or HbA1c result is. Testing can still be valuable for the right person, particularly those with a family history, kidney symptoms, or specific decisions ahead like kidney donation, but the test is best understood as a risk modifier rather than a screening test endorsed for everyone.

For potential living kidney donors of African ancestry, the implications are larger. Black living donors with a high-risk genotype showed greater decline in kidney function after donation than donors without it, and several transplant programs now include APOL1 status in donor evaluation. There is not yet consensus on whether such testing should be required, but knowing your genotype before that decision is made matters more than any other context for testing.

A nephrologist or genetic counselor familiar with APOL1 is the right person to help you build a plan, especially if you carry the high-risk pattern and have a family history of kidney disease, lupus, or HIV. Companion testing that pairs well with this result includes eGFR, cystatin C, urine albumin-to-creatinine ratio, and blood pressure tracking. Those numbers tell you whether the risk written in your genes is starting to show up in your body.

One Test, Lifelong Implications

Your APOL1 genotype does not change. You will get the same answer at 30, 50, and 70. There is no reason to retest unless the original variant call was uncertain or done by a non-clinical method like a direct-to-consumer SNP chip, in which case a confirmatory clinical-grade assay is appropriate. The value of this test is not in repeating it. It is in integrating the result into the kidney monitoring and intervention decisions you make for the rest of your life.

If your result is high-risk, that means a baseline kidney workup now, and ongoing kidney filtration and urine albumin testing at a cadence your clinician sets, often at least annually. Earlier evaluation makes sense for any unexplained protein in the urine or drop in filtration. If you develop a condition that can act as a trigger, like HIV or an autoimmune disease, the testing cadence should tighten further. Formal guideline-based monitoring schedules for APOL1 carriers do not yet exist, so the right cadence is a conversation with your clinician informed by your overall risk picture.